Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Facts are we are in the middle of a 2w study for one of the most toxic chemo drugs on earth. That didn’t have dose limiting side effects at 3.5 times the dose with no MTD. Yeah I’m very happy to keep adding based on the risk reward Matrix here. You guys can continue to sulk and moan about the placing and Smith, I’m happy to take advantage of the opportunity presented in front of me. Good luck Craig.
told you before i’m an investor i don’t care about the short term market fluctuations, would the science be in the wrong hands if they release case studies to sky news and this surges to all time highs next week, you would probably change your tune. sorry but you are confusing short term share price volatility to the likely hood of future success that’s totally bo11ocks. they are different, keep ****ging smith all you like, however the science is delivering stunning data so far and no reason to think the 50p raise will make it any less likely to get fda approval in the longer term. especially with the current commercial appointments made.
Was talking about TR1’s for institutional investors REDUCING holiding’s selling down percentages since Dec. Apologies for the confusion, I expect TR1’s to be issued for potentially the USA fund and Healthcare fund in due course not sure time scale to issue them though.
“AVA6000 is not likely to see FDA approval anytime soon, at least before the current cash pot runs out. Which puts to bed the cold ones theory.”
What’s stopping AVA6000 getting approved for STS phase 2 we have cash runaway Q1 2026 and a partnership being done for phase 3 for international exposure done under different cancer types (breast etc). My theory works fine. Thanks for commenting though much appreciated.
Let’s see what happens, if the vast majority of PI’s want Smith out then he will get punted, unfortunately we are in an echo chamber where management discontent based on not selling at 130 and buying back at 50p may seem stronger than it actually is. I’m extremely convinced this placing was done to go solo because the data is so compelling, not to partner up in phase 1 as originally planned, they figured out they could get significantly better deals further on in the trial. Hence where we are.
“ I cannot knock your positivity but it’s impossible for me to ignore what has happened.”
Why do you think this isn’t actually the correct strategy for the LTH. If they can get this approved phase 2 solo and partner at way premiums for the platform than before phase 2, you might find the 19% dilution was a good deal. We don’t know the circumstances data or cost benefit analysis done on future deals rather than doing deals phase 1.
Yeah our NEW European health fund and NEW USA institutional investors (40 day black out) forward sold. True some institutions on the placing took advantage of forward selling on the drop from 130 however it won’t have been all of them, also it wouldn’t have been significant amounts as no TR1s were RNS’d.
“The science “working” is only half the battle, you need the structure and commercial know how to bring it to fruition.”
You don’t think Simon can bring this to fruition and get AVA6000 approved? The short term share price is irrelevant on the above. The institutions invested 26 million at 50p for the longterm commercial success of Avacta, don’t get long term investment opportunities, confused by the short term volatility of the market.
@Morris
Sorry but we have hired a commercial lead for therapeutics. He’s pretty experienced.
“Simon has over 26 years' commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America”
Institutional investors don’t pony up 26 million plus on blind faith when the interest rate at the moment is pretty attractive.
“Or to put it another way. If the share price remains at 50 pence when the next instalment is due.”
Why would the price remain at 50p when we are expecting a full update on new clinical data. Find it hilarious that this is still down at 50p in the first place.
1. Avacta confirmed timescales and safety previous RNS
2. The 34% discount (real terms was 50% discount based on the magnet price of 100) has been wiped out on approximately 19% dilution yet we are fully funded and science is improving. Thats not logical imo, based on sentiment not facts.
3. The convertible bond can be paid in cash anytime. No death spiral.
We are heading into the month of April, note in the previous RNS they still have patients dosed in the 3 week study, thats some amount of targeted Dox chemo being administered directly to the tumour site, wonder what the results are going to be.
Shareholders won’t be complaining, when the FDA eventually approves AVA6000.
1. No MTD found.
2. Biopsy data has shown proof of platform mechanism.
3. Dox kills cancer cells (been established since the 1960s)
4. Deemed safe at 3.5 times the normal standard dose of Dox. With no dose limiting side effects.
Remember why you invested in Avacta in the first place. Have a great day. 💯😊👍
I mean the results are still on schedule for the end of Q2 and the start of the phase 2 dose expansion end of year followed by phase 2 efficacy straight after. I am sure the team have everything In hand. Commercialisation is still 2026 happy days.
Think it’s very clear from Avacta they are going to give the FDA as much data as possible probably way over the top for a standard phase 1 trial. You don’t obtain 10 biopsies from 9 different patients in multiple cohorts if all you are looking at is safety in phase 1. I could be totally wrong however don’t think other companies, have done that phase 1.